PGT-A: Confirm Your Embryos' Chromosomal Integrity Before Transfer
PGT-A (Preimplantation Genetic Testing for Aneuploidy) is an advanced genetic screening method that examines the chromosome count of IVF embryos before transfer, using next-generation sequencing technology.
In short: PGT-A helps select chromosomally normal (euploid) embryos, reducing miscarriage risk and increasing the chance of achieving a healthy pregnancy in fewer transfer attempts.
What Is PGT-A Testing?
Chromosomal number abnormalities (aneuploidy) are among the leading causes of miscarriage and failed IVF cycles, and their frequency increases with maternal age. PGT-A examines a small number of cells taken from a blastocyst-stage embryo using next-generation sequencing to determine whether all 23 chromosome pairs are numerically normal.
This evaluation is carried out by experienced embryologists and the clinical genetics team, who use the results to identify the embryo with the highest implantation potential for transfer.
How Does the PGT-A Process Work?
• During IVF treatment, embryos are cultured in the laboratory to the blastocyst stage (day 5–6).
• A small number of cells are removed using a high-precision blastocyst biopsy technique, which does not affect the embryo's developmental potential.
• The sample is sent for chromosomal analysis using next-generation sequencing technology.
• Embryos are safely frozen (vitrified) during this process.
• Once results are available, the clinical team recommends the chromosomally normal embryo(s) for transfer.
Who Should Consider PGT-A Testing?
PGT-A is a valuable option for women of advanced maternal age (typically over 35); couples with a history of recurrent miscarriage; those who have experienced multiple failed IVF cycles; and any couple who wants to maximize their chances of pregnancy through single embryo transfer.
Expected Clinical Outcomes
• Identification of chromosomally normal (euploid) embryos for transfer
• Reduced risk of miscarriage and failed implantation
• Improved pregnancy success rate with single embryo transfer
• Fewer unnecessary transfer attempts and a shorter overall treatment timeline
Why Choose Turkey for This Service?
Turkey has become one of the world's most sought-after destinations for reproductive health and IVF treatment, offering experienced embryology teams and internationally standardized genetic laboratory infrastructure.
• A clear cost advantage compared to similar PGT-A programs in the US and Western Europe
• A multidisciplinary team of embryologists, reproductive endocrinologists, and clinical genetics specialists working under one roof
• High-precision genetic analysis based on next-generation sequencing
• Short waiting times for fast treatment planning and sample processing
• A comprehensive health tourism infrastructure offering organized travel, accommodation, and interpretation support for international patients
Frequently Asked Questions (FAQ)
Does PGT-A harm the embryo?
No. Blastocyst biopsy is a high-precision technique performed by experienced embryologists in a way that does not affect the embryo's development.
Does a normal PGT-A result guarantee pregnancy?
PGT-A significantly improves implantation chances by identifying chromosomally normal embryos, but chromosomal status is not the only factor affecting pregnancy success — factors such as the uterine environment also play a role.
What is the difference between PGT-A and PGT-M?
PGT-A evaluates the embryo's chromosome number (aneuploidy), while PGT-M tests whether a specific, known single-gene disease in the family has been passed on to the embryo.
How long does it take to get results?
The next-generation sequencing analysis process is typically completed within 1–2 weeks, during which embryos remain safely frozen.
How long do I need to stay in Turkey for this treatment?
Egg retrieval and embryo biopsy typically require a stay of about 2–3 weeks in Turkey; the transfer can be planned in a separate trip once genetic results are available.